PTW Announces Business Acquisition of LA-Based Art Powerhouse, 5518 Studios
PTW continues on their mission to be the go-to partner for innovation in the games industry with the business acquisition of premier art studio 5518 Studios. The industry-leading video games and tech services outsourcer announced their business acquisition of Los Angeles-based 5518 Studios; PTW is a long-time industry leader with an established and diverse dossier of top-tier clients and nearly 3 decades of experience in the games industry. PTW’s work spans across all platforms and all genres.
5518’s expertise ranges from high-quality concept & illustration art to character modeling & animation, along with everything in-between; PTW’s expansion ensures a greater range of skills, depth of talent, and overall expertise for their partners across the globe. Today’s announcement is an exciting step forward in PTW’s mission to provide full end-to-end co-development services to partners in the growing global games industry.
“Our mission is to revolutionize the digital entertainment sphere; adding 5518 to our team enables us to be one of the top development studios in the world. We will merge our existing game development brand- Orange Rock Studios- with 5518 under one name; our new brand will be perfectly poised to work alongside top-notch developers and publishers, building the best games & digital experiences around the world,” said Kasturi Rangan, Chief Product Officer of PTW. “When it comes to game development, we will now be a one-stop shop for external partnerships,” Rangan concluded.
PTW will be merging both Orange Rock and 5518 under a new name- 1518 Studios. The new brand will have a much stronger offering encompassing art, end-end game development, live ops, porting, product development, and staff augmentation (across Mobile, PC & Console). Michael Casalino, CEO and Co-founder of 5518 Studios added, “Our values and mission align so well with those of PTW; we each believe in strong relationships built on trust, passion, good communication, and high-quality games services.” 5518 COO and CO-founder Maxim Miheyenko concluded, “We are so excited to join the PTW family of brands.”
PTW CEO Deborah Kirkham concluded, “We are happy to welcome 5518 Studios and our new teams in Los Angeles, St. Petersburg, and Moscow to the PTW family. Expanding our global presence in the games industry is an important step in our mission of providing the best talent and the best technology to our partners around the world. Michael, Maxim, and their teams provide a level of expertise and energy which we can’t wait to bring to our partners.”
About PTW
PTW is a leading games, digital entertainment and interactive media solutions provider with 35 offices in 11 countries worldwide. Our range of services include quality assurance, localization, customer experience, engineering and development services, and audio production services. PTW brings nearly 3 decades of experience and the infrastructure to create customized support for projects and clients of all sizes.
PTW, comprised of global subsidiaries, is a UK-based holding company formed in 2016 under the umbrella of Poletowin Pitcrew Holdings, Inc. which is listed on the 1st Section of Tokyo Stock Exchange as 3657. POLE TO WIN is a registered trademark of Pole To Win Co., Ltd. in Japan and other countries. All rights reserved. For more information, visit https://www.ptw.com/
The PTW group includes SIDE, 1518 Studios, Entalize, The Game Dev Show, and OR Esports.
Stay connected with PTW on Facebook, Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005010/en/
Contact information
For queries related to PTW, please email:
Media Contacts:
Kaley Hurst
415-521-8709
Kaley.hurst@ptw.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom